Skip to main content
. 2023 May 3;13:1178428. doi: 10.3389/fonc.2023.1178428

Figure 3.

Figure 3

Kaplan-Meier analysis of progression-free survival in patients receiving the combination therapy of HAIC, lenvatinib plus PD-1 inhibitor, and HAIC plus lenvatinib therapy. HAIC, hepatic artery infusion chemotherapy; PD-1, programmed cell death-1.